CoChat

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

Open access
Fisman, Enrique Z., Tenenbaum, Alexander · 2021 · Cardiovascular Diabetology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 stimulates insulin secretion, inhibits glucagon secretion at pancreatic α cells and has also extrapancreatic influences as slowing of gastric emptying which increases the feeling of satiety. GIP is the main incretin hormone in healthy people, causative of most the incretin effects, but the insulin response after GIP secretion in type 2 diabetes mellitus (T2DM) is strongly reduced. Therefore, in the past GIP has been considered an unappealing therapeutic target for T2DM. This conception has been changing during recent years, since it has been reported that resistance to GIP can be reversed and its effectiveness restored by improving glycemic control. This fact paved the way for the development of a GIP receptor agonist-based therapy for T2DM, looking also for the possibility of finding a combined GLP-1/GIP receptor agonist. In this framework, the novel dual GIP and GLP-1 receptor agonist tirzepatide seems to be not just a new antidiabetic medication. Administered as a subcutaneous weekly injection, it is a manifold single pharmacological agent that has the ability to significantly lower glucose levels, as well as improve insulin sensitivity, reduce weight and amend dyslipidemia favorably modifying the lipid profile. Tirzepatide and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings. Obviously, it is too early to be overly hopeful since it is still necessary to determine the long-term effects of these compounds and properly verify the potential cardiovascular benefits. Anyway, we are currently facing a novel and very appealing therapeutic option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-021-01412-5

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Main physiological actions of the dual GIP and GLP-1 agonist tirzepatide. GIP—glucose-dependent insulinotropic polypeptide; GLP-1—glucagon-like peptide-1. Despite the similarities between the two incretins, it should be pinpointed that while GIP activity is mainly pancreatic, GLP-1 activity is systemic
Fig. 1 Main physiological actions of the dual GIP and GLP-1 agonist tirzepatide. GIP—glucose-dependent insulinotropic polypeptide; GLP-1—glucagon-like peptide-1. Despite the similarities between the two incretins, it should be pinpointed that while GIP activity is mainly pancreatic, GLP-1 activity is systemicCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 124

Metadata

Authors
Fisman, E. Z., & Tenenbaum, A.
Affiliations
Tel Aviv University (IL)
Corresponding author
Fisman, Enrique Z.
Venue
Cardiovascular Diabetology
Published
2021-11-24
Volume
20
Issue
1
Pages
225-225
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3216821013
Cited by
124
References
28
Citations by year
2026: 29 · 2025: 32 · 2024: 27 · 2023: 24 · 2022: 12
FWCI
11.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
No funding sources
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, GIP/GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretins, type 2 diabetes, insulin sensitivity, weight loss, dyslipidemia, cardiovascular safety
MeSH terms
Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Insulin, Lipids, Receptors, Gastrointestinal Hormone, Biomarkers, Treatment Outcome, Metabolic Syndrome, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. https://app.cochat.ai/papers/10.1186/s12933-021-01412-5
The paper
Fisman, E. Z., & Tenenbaum, A. (2021). The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01412-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.